CDK4 and neoplasm: Since deletion of cyclin-dependent kinase inhibitor 2A (CDKN2A), which is a tumor-suppressor gene and a negative regulator of CDK4/6, was found in this Ewing sarcoma patient's tumor, the efficacy of palbociclib was tested on the PDOX model of this tumor (13).